IPO of GEM Data Dao Dao Creative Board, Baili Tianheng welcomed the meeting on July 28th

On July 21, 2022, the Shanghai Stock Exchange Science and Technology Innovation Board of the Science and Technology Board was scheduled to hold a review meeting of the 64th listed committee of the 2022 on July 28, 2022. At that time, the application of IPO applications for science and technology boards of Sichuan Belle Sky Hango Pharmaceutical Co., Ltd. will be considered.

The company is a modern biomedical enterprise integrating drug research and development, production and marketing. It has the business sector and innovative biopharmaceutical business segments with chemical preparations and proprietary Chinese patent medicine preparations. The entire series of drug research and development production capacity of drugs (ADC drugs).

Photo source: the company's draft

According to the financial data of the draft, the company's revenue in 2019, 2020, and 2021 was 1.207 billion yuan, 1.013 billion yuan, and 797 million yuan, respectively. The corresponding net profit corresponding to the mother was 7.7309 million yuan, 37.9016 million yuan, and- 99.9913 million yuan.

It is worth noting that this is not the first IPO of Baili Tianheng. The company submitted the GEM prospectus in June 2014 and December 2015, and planned to break through the GEM.

However, due to the private name of some bank accounts, the average price of the main product has declined.

Before the IPO of this science and technology board, Baili Tianheng completed two rounds of inquiry and reply. In the first round of inquiry of the science and technology board, the Shanghai Stock Exchange mainly focused on Baili Tianheng's innovation attributes, generic drug core technology, and innovative drug business , Continuous operation capabilities, corporate structure and governance, marketing, R & D personnel and R & D investment, income and gross profit margins, government subsidies, accounts receivables, cash assets, product changes, previous IPO on -site inspection problems, etc. Essence

In the second round of inquiries, the Shanghai Stock Exchange focused on 7 issues including Baili Tianheng's generic drug business, innovative drug business, major new drug creation, promotion services, distribution models, and research and development expenses.

- END -